ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1509

Correlates of Skin Gene Expression Profile in Systemic Sclerosis

Shervin Assassi1, Jeffrey T. Chang2, Filemon K. Tan1, Minghua Wu3, Gloria A. Salazar Cintora1, Irum Zaheer4, Dinesh Khanna5, Daniel Furst6 and Maureen D. Mayes7, 1Rheumatology, Univ of Texas Health Science at Houston, Houston, TX, 2Univ of Texas Health Science at Houston, Houston, TX, 3Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 4Methodist Hospital, Houston, TX, 5Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 6Div of Rheumatology, UCLA Medical School, Los Angeles, CA, 7Internal Medicine/Rheumatology, Univ of Texas Health Science at Houston, Houston, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Genomics and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Skin global gene expression profiling indicates presence of distinct gene expression signatures in patients with systemic sclerosis (SSc). We examine the correlation of the skin gene expression profiles with clinical subsets of disease in a large sample of SSc patients.

Methods:

In this study, 61 SSc patients (61% diffuse disease, mean disease duration: 7.7 years) and 36 gender, ethnicity, and age matched controls were examined.  All skin biopsies were obtained from subjects’ arm and processed according to the same procedures.  In 40 SSc patients, the skin was affected at the biopsy site.  Global gene expression profiling was performed by Illumina HumanHT-12 arrays in one batch. Only 1 biopsy per subject was analyzed. Differentially expressed (DE) genes were detected in multivariable analysis with False Discovery Rate of 10% at the confidence level of 80%. Involved Canonical Pathways were identified by Ingenuity Pathway Analysis.  Unsupervised hierarchical clustering was performed with all expressed genes and after filtering the gene list with the previously published TGF-β, IL-13, and diffuse proliferative (Milano et al. 2008) signatures.  We also generated an interferon-α (IFN- α) inducible gene signature using control fibroblast treated with IFNa.

Results:

 The transcriptome of the majority of SSc patients differed from controls. Specifically, 2525 DE genes were identified, belonging to fibrotic, leukocyte extravasation, and oxidative phosphorylation pathways. However, there was significant heterogeneity among the SSc samples. We examined whether the observed heterogeneity correlated with known clinical subtypes of SSc. However, we could not identify any significant differential expression when patients were subgrouped by disease type (limited versus diffuse), antibody subtypes, treatment status (immunosuppression versus no immunosuppression), or disease duration. The presence of anti-RNP antibodies was the exception.  Comparison of anti-RNP positive to the anti-RNP negative patients resulted in 188 DE genes, belonging mainly to IFN pathways.  However, we detected prominent gene expression differences among SSc patients who have affected vs. unaffected skin at the biopsy site. This comparison resulted in 378 DE expressed genes, belonging to fibrotic and leukocyte extravasation pathways. This was further underscored by the fact that comparison of SSc affected skin to controls resulted in 3458 genes while comparing patients wit unaffected skin to controls resulted in only 38 DE genes. We next filtered our gene list by TGF-β, IL-13, diffuse proliferative, and IFN-α gene signatures in separate unsupervised clustering analyses. While these gene signatures were helpful in separating the majority of patients from controls, they did not correspond to known clinical subtypes of SSc including disease type and treatment status.    

Conclusion:

The majority of SSc patients have distinct (but heterogeneous) global gene expression profile when compared to controls. Within SSc group, the status of skin at the biopsy site is a major source of variability (affected versus unaffected skin). The observed heterogeneity in SSc transcriptomes does not correspond to the known clinical subtypes of disease.


Disclosure:

S. Assassi,

Savient Pharmaceuticals ,

5;

J. T. Chang,
None;

F. K. Tan,
None;

M. Wu,
None;

G. A. Salazar Cintora,
None;

I. Zaheer,
None;

D. Khanna,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

2,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

5,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

8;

D. Furst,
None;

M. D. Mayes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlates-of-skin-gene-expression-profile-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology